RxDoctor Payments Data

Martin Berk, MD

Advanced Heart Failure and Transplant Cardiology · Dallas, TXNPI 1033118278

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $333,065 of the $379,175 with a category attached, or 87.8%. 27 manufacturers reported payments, led by Johnson & Johnson at 31.3% of the total. Reporting peaked in 2024 at $94,651 and has fallen 54.1% since, to $43,478 in 2025. Among advanced heart failure and transplant cardiology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$379,175in general payments, 2019–2025

Across 388 payments — averaging $977.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$119K
  • Novo Nordisk$116K
  • Merck$82K
  • Boehringer Ingelheim$28K
  • Novartis$16K
  • Lilly USA, LLC$9K
  • plus $10K from 21 others
$1,488,907in research payments, 2019–2025

Across 841 payments — averaging $1770.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$342K
  • Janssen Research & Development, LLC$247K
  • American Regent$196K
  • Novartis$155K
  • AstraZeneca$100K
  • Cvrx, Inc.$82K
  • plus $367K from 8 others

What the payments were for

  • Consulting fees$8,5902%
  • Speaking & faculty fees$333,06588%
  • Travel & lodging$30,0288%
  • Food & beverage$7,3212%
  • Education$1700%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$379,175 in reported general payments places this provider in the 95th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.

See all advanced heart failure and transplant cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$346,749
Medicare patients
1,153
Services billed
4,557

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin442$409,852
EntrestoSacubitril/Valsartan229$267,881
EliquisApixaban248$267,287
XareltoRivaroxaban190$234,883
Synjardy XrEmpagliflozin/Metformin Hcl91$79,581
TrulicityDulaglutide36$41,945
NexlizetBempedoic Acid/Ezetimibe50$39,222
VerquvoVericiguat30$37,986
FarxigaDapagliflozin Propanediol37$33,511
OzempicSemaglutide26$29,336
Repatha SureclickEvolocumab33$26,057
Ezetimibe754$19,582
MounjaroTirzepatide17$18,284
BrilintaTicagrelor12$13,270
Rosuvastatin Calcium801$10,259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$27,600$489,433533 claims
NovartisEntresto$16,495$267,881229 claims
PfizerEliquis$121$267,287248 claims
Johnson & JohnsonXarelto$118,780$234,883190 claims
Lilly USA, LLCTrulicity, Mounjaro$8,877$60,22953 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$5,938$48,49563 claims
AstraZenecaFarxiga, Brilinta$58$46,78149 claims
MerckVerquvo$82,140$37,98630 claims
Novo NordiskOzempic$115,694$29,33626 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.

Other advanced heart failure and transplant cardiology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →